Modeling suggests SARS-CoV-2 rebound after nirmatrelvir-ritonavir treatment is driven by target cell preservation coupled with incomplete viral clearance

ABSTRACT In a subset of SARS-CoV-2-infected individuals treated with the antiviral nirmatrelvir-ritonavir, the virus rebounds following treatment. The mechanisms driving this rebound are not well understood. We used a mathematical model to describe the longitudinal viral load dynamics of 51 individu...

Deskribapen osoa

Xehetasun bibliografikoak

Egile Nagusiak:	Tin Phan, Ruy M. Ribeiro, Gregory E. Edelstein, Julie Boucau, Rockib Uddin, Caitlin Marino, May Y. Liew, Mamadou Barry, Manish C. Choudhary, Dessie Tien, Karry Su, Zahra Reynolds, Yijia Li, Shruti Sagar, Tammy D. Vyas, Yumeko Kawano, Jeffrey A. Sparks, Sarah P. Hammond, Zachary Wallace, Jatin M. Vyas, Jonathan Z. Li, Mark J. Siedner, Amy K. Barczak, Jacob E. Lemieux, Alan S. Perelson
Formatua:	Artigo
Hizkuntza:	Inglês
Argitaratua:	American Society for Microbiology 2025-03-01
Saila:	Journal of Virology
Gaiak:	SARS-CoV-2 viral rebound nirmatrelvir-ritonavir antiviral therapy target cell preservation mathematical model
Sarrera elektronikoa:	https://journals.asm.org/doi/10.1128/jvi.01623-24
Etiketak:	Etiketa erantsi Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!